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Abstract
Background/aims: Breast cancer metastasis suppressor 1 (BRMS1) blocks metastasis in melanoma xenografts;
however, its usefulness as a biomarker in human melanomas has not been widely studied. The goal was to
measure BRMS1 expression in benign nevi, primary and metastatic melanomas and evaluate its impact on disease
progression and prognosis.
Methods: Paraffin-embedded tissue from 155 primary melanomas, 69 metastases and 15 nevi was examined for
BRMS1 expression using immunohistochemistry. siRNA mediated BRMS1 down-regulation was used to study
impact on invasion and migration in melanoma cell lines.
Results: A significantly higher percentage of nevi (87%), compared to primary melanomas (20%) and metastases
(48%), expressed BRMS1 in the nucelus (p < 0.0001). Strong nuclear staining intensity was observed in 67% of nevi,
and in 9% and 24% of the primary and metastatic melanomas, respectively (p < 0.0001). Comparable cytoplasmic
expression was observed (nevi; 87%, primaries; 86%, metastases; 72%). However, a decline in cytoplasmic staining
intensity was observed in metastases compared to nevi and primary tumors (26%, 47%, and 58%, respectively, p <
0.0001). Score index (percentage immunopositive celles multiplied with staining intensity) revealed that high
cytoplasmic score index (≥ 4) was associated with thinner tumors (p = 0.04), lack of ulceration (p = 0.02) and
increased disease-free survival (p = 0.036). When intensity and percentage BRMS1 positive cells were analyzed
separately, intensity remained associated with tumor thickness (p = 0.024) and ulceration (p = 0.004) but was
inversely associated with expression of proliferation markers (cyclin D3 (p = 0.008), cyclin A (p = 0.007), and
p21
Waf1/Cip1 (p = 0.009)). Cytoplasmic score index was inversely associated with nuclear p-Akt (p = 0.013) and
positively associated with cytoplasmic p-ERK1/2 expression (p = 0.033). Nuclear BRMS1 expression in ≥ 10% of
primary melanoma cells was associated with thicker tumors (p = 0.016) and decreased relapse-free period (p =
0.043). Nuclear BRMS1 was associated with expression of fatty acid binding protein 7 (FABP7; p = 0.011), a marker
of invasion in melanomas. In line with this, repression of BRMS1 expression reduced the ability of melanoma cells
to migrate and invade in vitro.
Conclusion: Our data suggest that BRMS1 is localized in cytoplasm and nucleus of melanocytic cells and that
cellular localization determines its in vivo effect. We hypothesize that cytoplasmic BRMS1 restricts melanoma
progression while nuclear BRMS1 possibly promotes melanoma cell invasion.
Please see related article: http://www.biomedcentral.com/1741-7015/10/19
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Although melanomas accounts for only 4% of all derma-
tological cancers, they are responsible for approximately
80% of skin cancer-related deaths. In early stages, mela-
nomas can be treated surgically and 5-year survival rate
exceed 80%. However, less than 15% of patients having
metastatic disease (stage IV) can expect to survive 5
years as there are few or no therapeutic options. The
molecular mechanisms responsible for melanoma devel-
opment and progression are not completely understood.
Thus, novel diagnostic and prognostic biomarkers as
well as improved treatment strategies are urgently
needed [1].
Breast cancer metastasis suppressor 1 (BRMS1) was
originally identified following differential expression
comparisons of chromosome 11 microcell hybrids in a
human breast carcinoma cell line and was further
mapped to chromosome fragment 11q13, a region fre-
quently altered in melanomas [2]. Re-expression of
BRMS1 in human breast, non-small cell lung (NSCL)
and ovarian carcinomas and in melanoma cell lines
resulted in marked reduction of metastasis without
blocking orthotopic tumor growth [3].
Although BRMS1 has been described as a predomi-
nantly nuclear protein, it has recently become clear that
it is also localized in the cytoplasm [4,5]. As part of the
Sin3:histone deacetylase transcription complex [6],
BRMS1 affects metastasis by directly or indirectly
repressing expression of pro-metastatic genes and
enhancing the expression of other anti-metastatic genes
[7]. Furthermore, BRMS1 differentially regulates cancer
cell responses to growth factor signaling. Thus, BRMS1
reduces downstream PI3-kinase/Akt signaling by altering
phosphoinositide pools and/or by inhibiting epidermal
growth factor receptor expression [8]. BRMS1 also
represses NF-B transcriptional activity, urokinase-type
plasminogen activator and osteopontin [9] expression, as
well as upregulates expression of anti-metastatic micro-
RNA [10]. In breast, ovarian and NSCL carcinomas,
BRMS1 suppresses metastasis by inhibiting growth
initiation at secondary sites (i.e., colonization) without
preventing primary tumor growth [11,12]. In NSCLC,
BRMS1 expression decreased migration and invasion
[12]. Similarly, melanoma cells re-expressing BRMS1
were less invasive and had restored intercellular com-
munication [13].
In a subgroup of patients suffering from breast cancer,
loss of tumor expression of BRMS1 protein was asso-
ciated with reduced disease-free survival [14]. Further-
more, a shift from nuclear to cytoplasmic BRMS1
expression was found associated with highly proliferative
estrogen receptor negative breast cancers [4]. In
NSCLC, expression of BRMS1 protein was associated
with increased patient survival [12]. Recently, Li et al.
[15] observed decreased BRMS1 protein in metastatic
melanomas compared to benign nevi and primary
tumors as well as an association with tumor stages and
worse prognosis. In contrast to these findings, Kelly et
al. [16] found no correlation between BRMS1 mRNA
level and breast cancer metastasis to regional lymph
nodes, while Lombardi et al. [17] showed that high
BRMS1 mRNA expression correlates with poor prog-
nosis for patients with breast cancer. Although the
mRNA findings are interesting, we have previously
reported that mRNA and protein levels for BRMS1 do
not always correlate [18]; therefore, interpretation
should be done with caution. Nonetheless, although
recent literature suggest that BRMS1 may play roles
during tumor progression other than the metastasis sup-
pressor function originally suggested, this study was
undertaken to investigate the importance of BRMS1
expression and subcellular localization on melanoma
progression.
Materials and methods
Clinical melanoma specimens
Formalin-fixed, paraffin-embedded tissue from 155 pri-
mary melanomas and 69 metastases, as well as 15
benign nevi, was examined for expression of BRMS1
protein. Of the primaries, 93 were classified as superfi-
cial spreading (SSM) and 62 as nodular melanoma
(NM). Clinical follow-up was available for all patients.
The study was approved by the Regional Committee for
medical Research Ethics in Norway.
Immunohistochemical analysis
Three-μms e c t i o n sm a d ef r o mf o r m a l i n - f i x e dp a r a f f i n
embedded tissues were immunostained using the Dako
EnVision™+ system (K8012, Dako Cooperation, CA,
USA). Deparaffinization, rehydration and target retrieval
were performed in one operation in a Dako PT-link and
EnVision™ Flex target retrieval solution with high pH.
To block endogenous peroxidase the sections were trea-
ted with Dako blocking reagent for 5 minutes. Sections
were incubated with monoclonal BRMS1 antibody
(clone 3a1.21) (supplied by Dr. Welch) diluted 1:500 (2
μgI g G 1/mL) [19] for 30 minutes. Thereafter, the sec-
tions were incubated with Dako EnVision™ FLEX+
mouse linker for 15 minutes followed by incubation
with Dako EnVision™ FLEX/HRP for an additional 30
minutes. For visualization of staining, the sections were
treated with AEC+ High sensitivity Substrate Chromo-
gen Ready-to-use (K3469, Dako) (paraffin-embedded tis-
sue) or 3’3-diaminobenzidine tetra-hydrochloride (DAB)
(cell lines), counterstained with haematoxylin and
mounted from water in Dako Aqueous Mounting
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known expression of BRMS1 was used as positive con-
trol, whereas negative controls included substitution of
monoclonal antibody with mouse myeloma protein of
the same subclass and concentration as the monoclonal
antibody. Four semi-quantitative classes were used to
describe staining intensity (absent, 0; weak, 1; moderate,
2; strong, 3) and percentage of positive tumor cell:
absent, 0; < 10%, 1; 10-50%, 2; > 50%, 3). By multiplying
intensity score with extent score, a score index was cal-
culated ranging from 0 to 9. Staining in cytoplasm and
nucleus were evaluated separately. BRMS1 expression in
more than 10% of the tumor cells was considered as
high percentage, while moderate and strong staining
intensity were considered as strong. Similarly, a score
index of ≥ 4 was considered as high. Immunohistochem-
ical staining of cyclin D1, cyclin D3, cyclin A, p21
Waf1/
Cip1 p27
Kip1, p-ERK1/2, p-Akt, and FABP7 has been per-
formed previously [20-26].
Cell cultures and small interfering RNA (siRNA)
transfection
The WM239 cell line was kindly provided by Dr. Meen-
hard Herlyn, (Wistar Institute, Philadelphia, PA)
whereas the FEMX-1 cell line was established from a
lymph node metastasis obtained from a melanoma
patient treated at the Norwegian Radium Hospital, Oslo
University Hospital [27]. 1 × 10
6 cells were plated 24
hrs prior to transfection in T75 culture flasks containing
RPMI 1640 medium (Lonza, Verviers, Belgium) supple-
mented with 5% foetal bovine serum (FBS) (PAA
Laboratories, GMbH, Austria) and 2 mM L-glutamine
(GibcoBRL, Paisley, UK). The cells were transfected with
25 nM siRNA targeting BRMS1 (OligoID: HSS177871)
or stealth RNAi siRNA negative control in 37.5 uL Lipo-
fectamine 2000 according to the manufactures instruc-
tions (Invitrogen, Carlsbad, CA). The siRNA/
lipofectamine 2000 mixture was added in a total of 10
mL OptiMEM to each flask (all reagents and siRNA
were from Invitrogen. Six hrs after transfection, medium
was replaced with10 mL complete medium and 1 mL
[
3H] Thymidine (ARC St. Louis, MO) was added to the
cell cultures for migration and invasion assays. Twenty-
four hrs thereafter, the cells were detached by trypsini-
zation, counted and seeded in invasion chambers.
Quantitative real time RT-PCR
For mRNA expression analyses, the cells were detached
48 hrs after treatment with siRNA. Total RNA was
extracted using Trizol reagent (Invitrogen,) according to
manufacturer’s description and reverse transcribed with
the high capacity cDNA reverse transcription kit
(Applied Biosystems, Foster City, CA) using random pri-
mers. The real time RT-PCR analyses were performed as
previously described [26] with TaqMan Gene Expression
Assays (Hs00363036_m1 BRMS1, Hs99999908_m1
GUSB, Applied Biosystems). The relative BRMS1 mRNA
expression levels were normalized against housekeeping
gene beta-glucuronidase (GUSB). Each sample was run
in triplicate. The mean from three independent experi-
ments was calculated.
Migration and invasion assays
Migration and invasive properties were evaluated in a 24
well transwell chamber assay, 8 μMp o r es i z e( C o s t a r ,
Cambridge, MA). For analyzing invasiveness, the filters
were coated with 25 μg/filter Matrigel (BD Biosciences,
Bedford, MA) whereas migration was analyzed using
uncoated filters. 5 × 10
4 [
3H] Thymidine-labeled cells in
100 μL RPMI 1640 medium were applied in the upper
compartments, in triplicate wells. The lower compart-
ments were supplied with 600 μL RPMI 1640 medium
and 5% FBS as chemo attractant. After 48 hrs, the cells
on the upper and lower parts of the filters were
removed separately using cotton-tipped swabs, and
incorporated [
3H] Thymidine was counted in a liquid
scintillation analyzer (Packard Instrument Company,
Chicago, IL). Migration/invasion was assessed as the
ratio of counts obtained from the lower compartments
compared to total counts of both compartments.
Statistical analysis
A comparison between variables was performed using
the c
2 test or the Fisher exact test. The relationship
between BRMS1 expression and mean tumor thickness
was evaluated using the Mann-Whitney 2-sample test.
Kaplan- Meier survival estimates and log-rank tests
were used to evaluate the survival data. Two-tailed
paired Student’s t-test was used to evaluate the in vitro
results. A p-value of less than 0.05 was considered sta-
tistically significant.
Results
Protein expression of BRMS1 was analyzed by immuno-
histochemistry in a panel of paraffin-embedded benign
nevi and primary and metastatic melanoma tissues as
well as in two melanoma cell lines. Heterogeneous cyto-
plasmic and/or nuclear expression was observed. How-
ever, BRMS1 immunoreactivity was not found to
accumulate in specific parts of the tumor biopsies. The
results are summarized in Table 1 and illustrated in Fig-
ure 1. A significantly higher percentage of benign nevi
(87%) as compared to primary (20%) and metastatic
melanoma (48%), expressed BRMS1 in the nucleus (p <
0.0001). Cytoplasmic expression was found in 87% of
benign nevi and in 86% and 72% of primaries and
metastases, respectively. When staining intensity was
evaluated separately, strong nuclear intensity was
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24% of metastatic tumors (p < 0.0001). Whereas 47% of
the nevi and 58% of the primaries showed strong cyto-
plasmic staining intensity, a significant decline was
observed in the metastases (26%; p < 0.0001). When
score index (percentage of immunoreactive cells multi-
plied with staining intensity) was used as readout, high
nuclear score index (≥ 4) was observed in 53% of nevi
as compared to only 5% of the primary tumors. Interest-
i n g l y ,t h eo p p o s i t ew a so b s e rved for cytoplasmic stain-
ing; high cytoplasmic score index was seen in 50% of
the primaries but in only 7% of the nevi. Nuclear and
cytoplasmic score indexes were comparable in the
metastases (22% and 19%, respectively) (Table 1). In
melanoma cell lines, BRMS1 was localized mainly in the
nucleus, although some cytoplasmic expression was also
seen (Figure 1G, H).
Expression of BRMS1 in relation to clinical parameters
BRMS1 expression levels in superficial spreading and
nodular melanomas revealed no obvious differences
with regard to score index, number of immunoreactive
cells, nor staining intensity (Table 1). Moreover, no dif-
ferences were observed when comparing radial (tumor
thickness < 1 mm) and vertical (tumor thickness ≥ 1
mm) growth phase tumors. (data not shown). High cyto-
plasmic BRMS1 score index was significantly associated
with thinner tumors (p = 0.040), lack of ulceration (p =
0.020), and increased disease-free survival (p = 0.036;
Table 2 and Figure 2A). However, only staining intensity
remained associated with tumor thickness (p = 0.024)
and ulceration (p = 0.004) when intensity and percen-
tage BRMS1 immunoreactive cells were analyzed sepa-
rately (Table 3). Tumors with high percentage of cells
expressing nuclear BRMS1 were thicker (p = 0.016)
(Table 4) and had shorter relapse-free survival (p =
0.043) (Figure 2B). Neither nuclear score index nor
staining intensity were associated with any of the
examined clinical parameters (data not shown). Neither
cytoplasmic nor nuclear BRMS1 expression had impact
on overall survival (data not shown).
Relationship between cytoplasmic BRMS1 expression and
markers of proliferation and signal transduction
Since this panel of melanoma tissues has been pre-
viously analyzed for factors involved in cell proliferation
[20-22,24], it was of interest to examine the relationship
between BRMS1 expression and the levels of those fac-
tors. A significant inverse correlation between cytoplas-
mic BRMS1 score index and cyclin D3 expression was
observed (p = 0.001) (Table 2). Interestingly, however,
when analyzing percentage cytoplasmic BRMS1 positiv-
ity and staining intensity separately, a strong inverse
association was found between staining intensity and
cyclin D3 (p = 0.008), cyclin A (p = 0.007), and p21
Waf1/
Cip1 (p = 0.009) (Table 3). Furthermore, although not
significant, we found a negative association between
BRMS1 staining intensity and Ki67 expression (p =
0.068) (Table 3). No correlation was seen between cyto-
plasmic BRMS1 staining intensity and cyclin D1 or
p27
Kip1 expression (data not shown). Nuclear BRMS1
expression was not associated with markers of prolifera-
tion (data not shown).
It was demonstrated previously that expression of
BRMS1 is correlated with activation of the PI3-kinase/
Akt and NF-B signaling pathways [8,9,28]. Here we
present results showing that cytoplamic score index is
inversely correlated to nuclear p-Akt expression (p =
0.013), but positively associated with expression of acti-
vated cytoplasmic ERK1/2 (p = 0.033) (Table 2).
Nuclear BRMS1 expression is associated with invasive
properties
We have recently demonstrated an association between
protein expression of fatty acid binding protein 7
(FABP7) and proliferation and invasion of melanoma
Table 1 Expression of BRMS1 according to number of positive cases, intensity and subcellular localization
1No. positive (%) Intensity (%) Score index (%)
Nucleus Cytoplasm Nucleus Cytoplasm
Total Nucleus Cytoplasm Strong
2 Strong High
3 High
Nevi 15 (100) 13 (87) 13 (87) 10 (67) 7 (47) 8 (53) 1 (7)
Primary
Melanomas
136 (88) 32 (20) 134 (86) 14 (9) 90 (58) 7 (5) 77 (50)
SSM
4 83 (89) 17 (20) 82 (88) 7 (8) 61 (66) 2 (2) 54 (58)
NM
5 53 (85) 15 (24) 52 (84) 7 (11) 29 (45) 5 (8) 23 (37)
Metastases 62 (90) 33 (48) 50 (72) 17 (24) 18 (26) 15 (22) 13 (19)
1Includes all positive cases
2Strong staining intensity includes moderate and strong intensity
3High score index defined as ≥ 4
4SSM; Superficial spreading melanoma
5NM; Nodular melanoma
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Page 4 of 10Figure 1 Immunohistochemical staining of BRMS1 in benign nevi showing cytoplasmic and nuclear (A,) and nuclear only expression
(B), primary melanomas with cytoplasmic expression (C, D) and metastatic melanomas demonstrating cytoplasmic and nuclear (E)
and cytoplasmic only immunoreactivity (F). In the two melanoma cell lines (G, H) BRMS1 is localized mainly in the nucleus, although some
cytoplasmic expression is also present.
Slipicevic et al. BMC Cancer 2012, 12:73
http://www.biomedcentral.com/1471-2407/12/73
Page 5 of 10cells [26]. When examining the melanoma panel for a
possible association between BRMS1 and FABP7, a sig-
nificant correlation between nuclear BRMS1 expression
(percentage of immunoreactive cells) and the level of
FABP7 (p = 0.011) (Table 4) was observed.
To examine in more detail whether BRMS1 affects
migration and invasion of melanoma cells we transiently
down-regulated BRMS1 expression using siRNA in two
metastatic melanoma cell lines (WM239, FEMX-1) (Fig-
ure 3A) and performed a transwell chamber invasion/
migration assay. As demonstrated in Figure 3B, repres-
sion of BRMS1 significantly reduced invasion in both
cell lines (WM239; p = 0.047, FEMX-1; p = 0.016)
whereas migration was only repressed in the WM239
cells (WM239; p = 0.013, FEMX-1; p = 0.43).
Discussion
Immunohistochemistry was applied to examine the level
of BRMS1 protein in a panel of benign nevi and primary
and metastatic melanomas in order to evaluate the
impact of altered expression on clinical outcome. In
accordance with previous studies demonstrating higher
mRNA and/or nuclear BRMS1 protein expression in
normal or benign tissues as compared to malignant
tumors [4,12,29], BRMS1 was highly expressed in the
nucleus of benign nevi whereas only a minor fraction of
Table 2 Relationship between cytoplasmic BRMS1 score index, ulceration, tumor thickness, cyclin D3 and activation of
ERK1/2 and Akt
Cytoplasmic BRMS1 score index
Clinical parameter Expression Low High
a P
Mean tumor depth (mm) 3.60 (3.29)
b 2.42 (2.46) 0.040
No 41 53
Ulceration Yes 30 16 0.020
Marker
Cyclin D3 Low 42 57
High 32 12 0.001
Low 43 29
Cytoplasmic p-ERK High 32 46 0.033
Low 46 59 0.013
Nuclear p-Akt High 26 12
aHigh score index defined as ≥ 4
Low protein expression was defined as immunoreactivity in less than 5% (cyclin D3) [21]
in < 50% of the tumor cells (p-Akt) [25], or total lack of expression (p-ERK) [23]
bSD
AB
High
Low High
Low
Figure 2 Kaplan-Meier curve demonstrating relationship between BRMS1 cytoplasmic score index (A) and between percentage of
cells expressing nuclear BRMS1 (B) and disease-free survival.
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expression profile. Our findings also partially agree with
the study by Li et al. [15] who observed a decline in
nuclear BRMS1 expression from dysplastic nevi to pri-
mary melanomas. A possible explanation for the more
dramatic decline in our study may be that, in the pre-
vious study, malignant lesions were compared to dys-
plastic nevi while benign nevi of compound and
intradermal subtypes where utilized in our investiga-
tions. Thus, it may be speculated that loss of nuclear
BRMS1 expression is an early event, distinguishing com-
mon and dysplastic nevi.
Although BRMS1 has been recognized as a mainly
nuclear protein, Rivera et al. [5] recently showed that
BRMS1 contains both nuclear import and export signals,
and implied that nuclear-cytoplasmic shuttling may
represent a novel mechanism for altering the activity or
function of BRMS1. The data in this study and a recent
immunocytochemistry report in breast cancer [4] are
consistent with that hypothesis. During melanocyte
transformation and progression, BRMS1 appears to relo-
calize from the nucleus to the cytoplasm. Additionally,
cytoplasmic staining intensity appeared to have a more
pronounced impact than number of immunoreactive
cells, suggesting that the level of BRMS1 protein has to
reach a threshold level to have an effect on cellular
behavior. Although there was no obvious difference in
the percentage of tumor cells expressing BRMS1 in the
cytoplasm, there was a clear decline in staining intensity
in metastases as compared to nevi and primary tumors.
Our findings are, however, in contrast to the study by Li
et al., [15] who observed predominantly nuclear BRMS1
expression in benign and malignant melanocytic cells.
One explanation for this discrepancy may be the use of
different antigen retrieval and detection methods.
Frolova et al. [4] reported that cytoplasmic BRMS1
was associated with increased proliferation in estrogen
receptor-negative breast cancers. In contrast, the mela-
noma samples used here show that cytoplasmic expres-
sion of BRMS1 is inversely associated with markers of
proliferation, cyclin D3, cyclin A, Ki67, p21
Waf1/Cip1.
When coupled with our previously demonstrated asso-
ciations between cell cycle regulators, numbers of mito-
sis and disease progression [21,22,24], the data
presented further strengthen the hypothesis that cyto-
plasmic BRMS1 is associated with a less aggressive mel-
anoma phenotype (i.e., thinner tumors, less ulcerated,
longer survival).
ERK1/2, when sequestered in the cytoplasm, has been
suggested to prevent transcription of pro-survival and
proliferative proteins as well as enhance the activity of
pro-apoptotic cytoplasmic proteins [30]. Furthermore,
whereas Gayer et al. [31] recently suggested that exclud-
ing ERK1/2 from the nucleus inhibits proliferation, Jova-
novic et al.[32] observed that the presence of activated
ERK1/2 in the cytoplasm of melanomas was associated
with better prognosis. In line with this, we demonstrated
a strong positive association between BRMS1 and acti-
vated ERK1/2 when both were localized in the cyto-
plasm. Moreover, we also observed a strong inverse
association between cytoplasmic BRMS1 expression and
accumulation of activated p-Akt in the nucleus. Prior
studies observed a negative association between BRMS1
and activation of PI3-kinase/Akt signaling [28,33], which
is consistent with the well documented evidence that
PI3-kinase/Akt signaling affects numerous steps of the
metastatic cascade, including proliferation, apoptosis,
migration and invasion [34]. In thyroid cancer, nuclear
localization of activated Akt was associated with tumor
Table 3 Relationship between intensity of BRMS1
expression, ulceration, tumor thickness and markers of
proliferation
Intensity of
cytoplasmic
BRMS1 staining
Clinical parameter Expression Weak Strong
a P
Mean tumor depth
(mm)
3.26 (3.11)
b
1.92
(1.89)
0.024
Ulceration No 71 23
Yes 44 2 0.004
Marker
Low 53 19
Cyclin A High 65 6 0.007
Low 70 20
Ki67 High 48 5 0.068
Cyclin D3 Low 76 23
High 42 2 0.008
Low 32 17
p21 High 31 3 0.009
aLow protein expression was defined as immunoreactivity in less than 5% of
the tumor cells
(cyclin A, Ki67, cyclin D3, p21)[21,22,24]
bSD
Table 4 Relationship between nuclear BRMS1 expression,
tumor thickness, and expression of FABP7
Expression of
nuclear BRMS1
Clinical parameter Expression Low
a High P
Mean tumor depth
(mm)
2.72 (2.69)
c
4.70
(3.85)
0.016
Marker
Low
b 52 1
FABP7 High 74 15 0.011
a Low when < 10% of the tumor cells express BRMS1
bLow when < 5% of the tumor cells express FABP7 [26]
cSD
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Page 7 of 10invasion and metastasis [35]. Together these results sug-
gest that cytoplasmic BRMS1 may at least partly nega-
tively regulate melanoma progression and metastasis
through sequestering of activated ERK1/2 in the cyto-
plasm and by preventing accumulation of nuclear active
Akt.
In contrast to the results obtained in another melanoma
cohort [15], as well as in breast [14] and NSCL cancers
[12] our study showed that high nuclear expression of
BRMS1 was associated with more aggressive tumors and
shorter disease-free survival. The higher nuclear expres-
sion of BRMS1 found in benign nevi than in primary
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Figure 3 Effect of BRMS1 on migration and invasion of melanoma cells. BRMS1 expression was transiently down-regulated using siRNA in
the metastatic melanoma cell lines WM239 and FEMX-1 (A) and analyzed for migration and invasion ability in a transwell chamber assay (B). Bars
represent mean ratio of cells ± SE of cells in the lower compartment compared to total number of cells in both compartments from at least
three independent biological experiments. WM239: invasion; p = 0.047, migration; p = 0.013, FEMX-1; invasion; p = 0.016, migration; p = 0.43.
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Page 8 of 10melanomas or metastases seems contradictory to the asso-
ciation to prolonged disease-free survival for patients hav-
ing low nuclear tumor expression of BRMS1. As yet, we
are unable to explain this phenomenon, but benign nevi
are commonly terminal lesions as opposed to melanomas.
Thus, the molecular events regulating these processes
might differ. In this regard it has been shown that mutated
B-Raf plays a role in inducing senescence in melanocytes,
whereas in melanomas it contributes to oncogenesis [36].
Furthermore, in a recent study we showed that expression
of fatty acid binding protein 7 (FABP7) is higher in benign
nevi than in melanomas, still FABP7 was suggested to con-
tribute to disease progression, most likely by increasing
tumor cell invasion [26]. Interestingly, we observed a
strong positive association between nuclear BRMS1 and
FABP7 expression, suggesting that nuclear BRMS1 may, in
fact, increase the invasive potential. In support of this, we
showed that down-regulation of BRMS1 in two metastatic
melanoma cell lines, expressing predominantly nuclear
BRMS1, reduced the invasive ability.
Although it has not yet been verified at the protein
level, the mRNA for various splice variants that are dif-
ferently expressed in metastatic and non-metastatic
breast cancer cell lines have been identified [18,37].
Thus, it may be speculated that benign nevi and primary
and metastatic melanomas express different BRMS1 var-
iants with different biological functions.
Conclusion
The BRMS1 metastasis suppressor is localized in both
the cytoplasm and nucleus of melanocytic tumors. Cel-
lular localization corresponds to different effects, cyto-
plasmic BRMS1 appears to restrict tumor progression
by negatively affecting cell proliferation, sequestering p-
ERK1/2 in the cytoplasm and by preventing accumula-
tion of nuclear p-Akt while nuclear BRMS1 may pro-
mote melanoma invasion, perhaps by its association
w i t hF A B P 7 .C l e a r l y ,w h i l eB R M S 1m a yh a v es h a r e d
roles in some tumor types, it is apparent that those
roles can vary by the cell type from which a tumor
arises and also by the tumor microenvironment.
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